Treatment of dementia with neurotransmission modulation

Bibliography

• BARBER R, PANIKKAR A, MCKEITH IG: Dementia with Lewy bodies: diagnosis and management. Int. .1. Geriatr. Psychiatry (2001) 16:S12–S18.
   PubMed Web of Science ®Google Scholar
• LEYS D, PASQUIER F, PARNETTI L: Epidemiology of vascular dementia. Haemostasis (1998) 28:134–150.
   PubMedGoogle Scholar
• WELCH HG, WALSH JS, LARSON EB: The cost of institutional care in Alzheimer's disease: nursing home and hospital use in a prospective cohort. J. Am. Geriatr. Soc. (1992) 40:221–224.
   PubMed Web of Science ®Google Scholar
• COYLE JT, PRICE DL, DELONG MR: Alzheimer's disease: a disorder of cholinergic innervation. Science (1983) 219:1184–1190.
   PubMed Web of Science ®Google Scholar
• DAVIES P, KATZMAN R, TERRY RD: Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer's disease and Alzheimer senile dementia. Nature (1980) 288:279–280.
   PubMed Web of Science ®Google Scholar
• MCKEITH IG: Dementia with Lewy bodies. Br. J. Psychiatry (2002) 180:144–147.
   PubMed Web of Science ®Google Scholar
• ZEKRY D, HAUW JJ, GOLD G: Mixeddementia: epidemiology, diagnosis, and treatment. J. Am. Geriatr. Soc. (2002) 50:1431–1438.
   PubMed Web of Science ®Google Scholar
• SADOT E, GURWITZ D, BARG J et al:Activation of M1 muscarinic acetylcholine receptor regulates tau phosphorylation in transfected PC12 cells. Neurochem. (1996) 66:877–880.
   PubMed Web of Science ®Google Scholar
• NITSCH RM, SLACK BE, WURTMAN RJ, GROWDON JH: Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science (1992) 258:304–307.
   PubMed Web of Science ®Google Scholar
• FISHER A, MICHAELSON DM, BRANDEIS R et al.: M1 muscarinic agonists as potential disease-modifying agents in Alzheimer's disease. Rationale and perspectives. Ann. NY Acad. Sci. (2000) 920:315–320.
   PubMed Web of Science ®Google Scholar
• ••This paper presents good evidence tosupport a role for M1 agonists in altering AD progression by modification of arnyloid-P processing and dephosphorylation of tau proteins.
   Google Scholar
• AMENTA F, PARNETTI L, GALLAI V, WALLIN A: Treatment of cognitive dysfunction associated with Alzheimer's disease with cholinergic precursors. In effective treatments or inappropriate approaches. Mech. Ageing Dev. (2001) 122:2025–2040.
   PubMed Web of Science ®Google Scholar
• PARNETTI L, AMENTA F, GALLAI V: Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data. Mech. Ageing Dev. (2001) 122:2041–2055.
   PubMed Web of Science ®Google Scholar
• DE JESUS MORENO MORENO M: Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. Ther. (2003) 25:178–193.
   Google Scholar
• MOLLER H-J, HAMPEL H, HEGERL U, SCHMITT W, WALTER K: Double-blind, randomized, placebo-controlled clinical trial on the efficacy and tolerability of a physostigmine patch in patients with senile dementia of the Alzheimer type. Phannacopsychiatry (1999) 32:99–106.
   PubMed Web of Science ®Google Scholar
• DAVIS KL, THAL LJ, GAMZU ER et al: A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl. J. Med. (1992) 327:1253–1259.
   PubMed Web of Science ®Google Scholar
• FARLOW M, GRACON SI, HERSHEY LA et al.: A controlled trial of tacrine in Alzheimer's disease. JAMA (1992) 268:2523–2529.
   PubMed Web of Science ®Google Scholar
• KNAPP MJ, KNOPMAN DS, SOLOMON PR et al.: A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA (1994) 271:985–991.
   PubMed Web of Science ®Google Scholar
• KNOPMAN D, SCHNEIDER L, DAVIS K et al: Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality, Tacrine Study Group. Neurology (1996) 47:166–177.
   PubMed Web of Science ®Google Scholar
• OTT BR, LAPANE KL: Tarrine therapy is associated with reduced mortality in nursing home residents with dementia. I. Am. Ceriatr. Soc. (2002) 50:35–40.
   PubMed Web of Science ®Google Scholar
• WATKINS PB, ZIMMERMAN HJ, KNAPP MJ, GRACON SI, LEWIS KW: Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA (1994) 271:992–998.
   PubMed Web of Science ®Google Scholar
• VAN GOOL WA: Use of galantamine to treat vascular dementia. Lancet (2002) 360:1512.
   PubMedGoogle Scholar
• ROGERS SL, DOODY RS, MOHS RC et al.: Donepezil improves cognition and global function in Alzheimer's disease: a 15-week, double-blind, placebo-controlled study. Arch. Intern. Med. (1998) 158:1021–1031.
   PubMed Web of Science ®Google Scholar
• ROGERS SL, FARLOW MR, DOODY RS, MOHS R, FRIEDHOFF LT: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology (1998) 50:136–145.
   PubMed Web of Science ®Google Scholar
• ROGERS SL, FRIEDHOFF LT: Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study. Ear: Neuropsychopharmacol (1998) 8:67–75.
   PubMed Web of Science ®Google Scholar
• WINBLAD B, ENGEDAL K, SOININEN H et al.: A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology (2001) 57:489–495.
   PubMed Web of Science ®Google Scholar
• FELDMAN H, GAUTHIER S, HECKER J et al.: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology (2001) 57:613–620.
   PubMed Web of Science ®Google Scholar
• GAUTHIER S, FELDMAN H, HECKER J et al.: Efficacy of donepezil on behavioural symptoms in patients with moderate to severe Alzheimer's disease. Int. Psychogeriatr. (2002) 14:389–404.
   PubMed Web of Science ®Google Scholar
• TARIOT PN, CUMMINGS JL, KATZ IR et al.: A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. Am. Ceriatr. Soc. (2001) 49:1590–1599.
   PubMed Web of Science ®Google Scholar
• MEYER JS, CHOWDHURY MH, XU G, LI YS, QUACH M: Donepezil treatment of vascular dementia. Ann. NY Acad. Sci. (2002) 977:482–486.
   PubMed Web of Science ®Google Scholar
• ENZ A, AMSTUTZ R, BODDEKE H, GMELIN G, MALANOWSKO J: Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease. Frog. Brain Res. (1993) 98:431–438.
   PubMed Web of Science ®Google Scholar
• ROSLER M, ANAND R, CICIN-SAIN A et al.: Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. Br. Med. J. (1999) 6:633–638.
   Google Scholar
• FARLOW M, ANAND R, MESSINA J, HARTMENT R, VEACH J: A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur. Neurol (2000) 44:236–241.
   PubMed Web of Science ®Google Scholar
• WILKINSON DG, PASSMORE AP, BULLOCK R: A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. Int. J. Clio. Pract. (2002) 56:441–446.
   PubMed Web of Science ®Google Scholar
• MCKEITH IG, DEL SAR T, SPANO P et al.: Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet (2000) 356:2031–2036.
   PubMed Web of Science ®Google Scholar
• SANTOS MD, ALKONDON M, PEREIRA EF et al.: The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. MM. Pharmacol (2002) 61:1222–1234.
   PubMed Web of Science ®Google Scholar
• SAMOCHOCKI H, HOFFLE A, FEHRENBACHER A et al: Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not muscarinic acetylcholine receptors. J. Pharmacol Exp. The]: (2003) 305:1024–1036.
   PubMed Web of Science ®Google Scholar
• PAN YP, XU XH, WANG XL: Galantamine blocks delayed rectifier, but not transient outward potassium current in rat dissociated hippocampal pyramidal neurons. Neurosci. Lett. (2003) 336:37–40.
   PubMed Web of Science ®Google Scholar
• INAN SY, AKSU F, BAYSAL F: The effectsof some K+ channel blockers on scopolamine- or electroconvulsive shock-induced amnesia in mice. Eur. Pharmacol (2000) 407:159–164.
   PubMed Web of Science ®Google Scholar
• CAPSONI S, GIANNOTTA S, CATTANEO A: Nerve growth factor and galantamine ameliorate early sins of neurodegeneration in anti-nerve growth factor mice. Proc. Natl. Acad. Sci. USA (2002) 99:12432–12437.
   PubMed Web of Science ®Google Scholar
• RASKIND MA, PESKIND ER, WESSEL T, YUAN W: Galantamine in AD: a 6-month randomized, placebo- controlled trial with a 6-month extension. Neurology (2000) 54:2261–2268.
   PubMed Web of Science ®Google Scholar
• WILCOCK GK, LILIEFELD G, GAENS E: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Br. Med. (2000) 321:1445–1449.
   PubMed Web of Science ®Google Scholar
• TARIOT PN, SOLOMON PR, MORRIS JC et al.: A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology (2000) 54:2269–2276.
   PubMed Web of Science ®Google Scholar
• OLIN J, SCHNEIDER L: Galantamine for Alzheimer's disease. Cochrane Database Syst. Rev (2002):CD001747.
   Google Scholar
• ERKINJUNTTI T, KURZ A, GAUTHIER S et al.: Efficacy of galantamine in probably vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet (2002) 359:1283–1290.
   PubMed Web of Science ®Google Scholar
• PICCIOTTO MR, ZOLI M: Nicotinic receptors in aging and dementia. Neurobiol (2002) 53:641–655.
   Google Scholar
• PERRY E, MARTIN-RUIZ C, LEE M et al.: Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases. Eur. Pharmacol (2000) 393:215–222.
   PubMed Web of Science ®Google Scholar
• MARTIN-RUIZ CM, COURT JA, MOLNAR E et al.: Alpha4 but not alpha3 and alpha7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease. Neurochem. (1999) 73:1635–1640.
   PubMed Web of Science ®Google Scholar
• WANG H-Y, LEE DHS, D'ANDREA MR et al.: I3-Amyloid1_42 binds to a7 nicotinic acetylcholine receptor with high affinity. Biol. Chem. (2000) 275:5626–5632.
   Google Scholar
• GUAN ZZ, MIAO H, TIAN JY et al.: Suppressed expression of nicotinic acetylcholine receptors by nanomolar I3-amyloid peptides in PC12 cells. I Neural Transm. (2001) 108:1417–1433.
   PubMed Web of Science ®Google Scholar
• KIM S-H, KIM Y-K, JEONG S-J et al: Enhanced release of secreted form of Alzheimer's amyloid precursor protein from PC12 cell by nicotine. Ma PharmacoL (1997) 52:430–436.
   PubMed Web of Science ®Google Scholar
• LAHIRI D-K, UTSUKI T, CHEN D et al.: Nicotine reduced the secretion of Alzheimer's beta-amyloid precursor protein containing beta-amyloid in the rat without altering synaptic proteins. Ann. NY Acad. Sci. (2002) 965:364–372.
   PubMed Web of Science ®Google Scholar
• NORDBERG A, HELLSTROM-LINDAHL E, LEE M et al: Chronic nicotine treatment reduced beta-amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw). Neurochem. (2002) 81:655–658.
   PubMed Web of Science ®Google Scholar
• ••Evidence that nicotine may be reverseP-arnyloidosis when administered long term.
   Google Scholar
• ONO K, HASEFAWA K, YAMADA M, NAIKI H: Nicotine breaks down preformed Alzheimer's beta-amyloid fibrils M vitro. Biol. Psychiatry (2002) 52:880–886.
   PubMed Web of Science ®Google Scholar
• WHITE HK, LEVIN ED: Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease. Psychopharmacol (1999) 143:158–165.
   PubMed Web of Science ®Google Scholar
• LOPEZ-ARRIETA JM, RODRIGUEZ JL, SANZ F. Efficacy and safety of nicotine on Alzheimer's disease patients. Cochrane Database Syst. Rev (2001): CD001749.
   Google Scholar
• ARNERIC SP, SULLIVAN JP, BRIGGS CA et al: (5)-3-methyl 5 (1 methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and amdolytic activites: I. ha vitro characterization. Pharmacol Exp. Ther: (1994) 270:310–318.
   Google Scholar
• DECKER MW, BRIONI JD, SULLIVAN JP et al: (3)-3-methyl 5 (1 methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and amdolytic activites: II. In vivo characterization. Pharmacol Exp. Ther: (1994) 270:319–328.
   Google Scholar
• PRENDERGAST MA, TERRY AV Jr, JACKSON WJ et al: Improvement in accuracy of delayed recall in aged and non-aged, mature monkeys after intramuscular or transdermal administration of the CND nicotinic receptor agonist ABT-418. Psychopharmacology (Berl) (1997) 130:276–284.
   PubMed Web of Science ®Google Scholar
• POTTER A, CORWIN J, LANG Jet al.:Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease. Psychopharmacology (Berl) (1999) 142:334–342.
   Google Scholar
• KEM WR: The brain a7 nicotinic receptormay be an important therapeutic target for the treatment of Alzheimer's disease studies with DMXBA (GTS-21). Behav. Brain Res. (2000) 113:169–181.
   PubMed Web of Science ®Google Scholar
• KITAGAWA H, TAKENOUCHI T, AZUMA R: Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology(2003) 28:542–551.
   PubMed Web of Science ®Google Scholar
• MULLEN G, NAPIER J, BALESTRA M et al.: () Spiro [1 -azabicyclo [2.2.21octane-3,5'-oxazolidin-2'-onel, conformationally restricted analogue of acetylcholine, is a highly selective full agonist at the alpha 7 nicotinic acetylcholine receptor. Med. Chem. (2000) 43:4045–4050.
   Google Scholar
• LEVIN ED, BETTEGOWDA C, BLOSSERJ, GORDON J: AR-R17779, an alpha7 nicotinic agonist, improves learning and memory in rats. Behav. Pharmacol (1999) 10:675–680.
   PubMed Web of Science ®Google Scholar
• NISHIZAKI T, NOMURA T, MATUOKA T et al.: The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic Ach receptors. Brain Res. MoL Brain. Res. (2000) 80:53–62.
   PubMedGoogle Scholar
• ZHAO X, KURYATOV A, LINDSTROM JM, YEH JZ, NARAHASHI T: Nootropic drug modulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons. MM. Pharmacol (2001) 59:674–683.
   PubMed Web of Science ®Google Scholar
• YOSHII M, WATABE S: Enhancement of neuronal calcium currents by the nootropic agent, nefiracetam (DM-9384) in NG106-15 cells. Brain Res. (1994) 642:123–131.
   PubMed Web of Science ®Google Scholar
• HUANG CS, MA JY, MARSZALEC W, NARAHASHI T: Effects of the nootropic drug nefiracetam on the GABAA receptor-channel complex in dorsal root ganglion neurons. Neuropharmacology (1996) 35:1251–1261.
   PubMed Web of Science ®Google Scholar
• YAMADA K, NAKAYAMA S, SHIOTANI T, HASEGAWA T, NABESHIMA T: Possible involvement of the activation of voltage-sensitive calcium channels in the ameliorating effects of nefiracetam on scopolamine-induced impairment of performance in a passive avoidance task. J. Pharmacol Exp. Ther: (1994) 270:881–892.
   PubMed Web of Science ®Google Scholar
• YAMADA K, TANAKA T, MAMIYA T et al.: Improvement by nefiracetam of 3-amyloid-(1-42)-induced learning and memory impairment in rats. Br. J. Pharmacol (1999) 126:235–244.
   PubMed Web of Science ®Google Scholar
• FUKATSU T, MIYAKE-TAKAGI K, NAGAKURA A et al: Effects of nefiracetam on spatial memory function and acetylcholine and GABA metabolism in microsphere-embolized rats. Eur: .1. Pharmacol (2002) 453:59–67.
   Google Scholar
• CRESPI F: Nefiracetam. Dafichi Seiyaku. Curr. Opin. Investig. Drugs (2002) 3:788–793.
   Google Scholar
• DICKERSON JL, JANDA KD: Glycationof the amyloid 13-protein by a nicotine metabolite: A fortuitous chemical dynamic between smoking and Alzheimer's disease. Proc. Natl. Acad. Sci. USA (2003) 100:8182–8187.
   PubMed Web of Science ®Google Scholar
• SHIOZAKI K, ISEKI E, HINO H, KOSAKA K: Distribution of M1 muscarinic acetylcholine receptors in the hippocampus of patients with Alzheimer's disease and dementia with Lewy bodies - an immunohistochemical study. J. Neurol Sci. (2001) 193:23–28.
   PubMed Web of Science ®Google Scholar
• FLYNN DD, FERRARI-DILEO G, MASH DC, LEVEY Al: Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. Neurochem. (1995) 64:1888–1891.
   PubMed Web of Science ®Google Scholar
• PIGGOTT MA, OWENS J, O'BRIEN Jet al. Muscarinic receptors in basal ganglia in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease. I Chem. Neuroanat. (2003) 25:161–173.
   Google Scholar
• WIENRICH M, MEIER D, ENSINGER HA et al: Pharmacodynamic profile of the M1 agonist talsaclidine in animals and man. Life Sci. (2001) 68:2593–2600.
   PubMed Web of Science ®Google Scholar
• SHANNON HE, BYMASTER FP, CALLIGARO DO et al.: Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors. Pharmac. Exp. Ther. (1994) 269:271–281.
   PubMed Web of Science ®Google Scholar
• JAKUBIK J, TUCEK S, EL-FAKAHANY EE: Allosteric modulation by persistent binding of xanomeline of the interaction of competitive ligands with the M1 muscarinic acetylcholine receptor. Pharmacol Exp. Ther. (2002) 301:1033–1041.
   PubMed Web of Science ®Google Scholar
• BODICK NC, OFFEN WW, LEVEY Al et al.: Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer's disease. Arch. Neurol (1997) 54:465–473.
   PubMed Web of Science ®Google Scholar
• NITSCH RM, DENG M, TENNIS M, SCHOENFELD D, GROWDON JH: The selective muscarinic M1 agonist AF102B decreases levels of total Al3 in cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol. (2000) 48:913–917.
   PubMed Web of Science ®Google Scholar
• SABB AL, HUSBANDS GM, TOKOLICS J et al.: Discovery of a highly potent, functionally selective muscarinic agonist, WAY-132983 using rational drug design and receptor modelling. Bioorg. Med. Chem. Lett. (1999) 9:1895–1900.
   PubMed Web of Science ®Google Scholar
• BARTOLOMEO AC, MORRIS H, BUCCAFUSCO JJ et al.: The preclinical pharmacological profile of WAY-132983, a potent M1 preferring agonist. Pharmacol. Exp. Ther. (2000) 292:584–596.
   PubMed Web of Science ®Google Scholar
• THAL LJ, FORREST M, LOFT H, MENGEL H: LU25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease. Neurology(2000) 54:421–426.
   PubMed Web of Science ®Google Scholar
• LAPCHAK PA, ARAUJO DM, QUIRION R, COLLIER B: Binding sites for [3H]AF-DX 116 and effect of AF-DX 116 on endogenous acetylcholine release from rat brain slices. Brain Res. (1989) 496:285–294.
   PubMed Web of Science ®Google Scholar
• QUIRION R, WILSON A, ROWE W et al.: Facilitation of acetylcholine release and cognitive performance by an M2-muscarinic receptor antagonist in the aged memory-impaired rats.' Neurosci. (1995) 15:1455–1462.
   PubMed Web of Science ®Google Scholar
• DOUGLAS CL, BAGHDOYAN HA, LYDIC R: M2 muscarinic autoreceptors modulate acetylcholine release in prefrontal cortex of C57 BL/6J mouse.," Pharm. Exp. Ther. (2001) 299:960–966.
   Google Scholar
• LAI MK, LAI OF, KEENE D et al.: Psychosis of AD is associated with elevated muscarinic M2 binding in the cortex. Neurology(2001) 57:805–811.
   PubMed Web of Science ®Google Scholar
• TOMBAUGH GC, ROWE WB, CHOW AR, MICHAEL TH, ROSE GM: Theta-frequency synaptic potentiation in CA1 M vitro distinguishes cognitively impaired from unimpaired aged Fischer 344 rats. Neurosci. (2002) 22:9932–9940.
   PubMed Web of Science ®Google Scholar
• LACHOWICZ JE, LOWE D, DUFFY RA et al.: SCH 57790: a novel M2 receptor selective antagonist. Life Se/. (1999) 64:535–539.
   PubMed Web of Science ®Google Scholar
• CAREY GJ, BILLARD W, BINCH H et al.: SCH 57790, a selective muscarinic M2 receptor antagonist, releases acetylcholine and produces cognitive enhancement in laboratory animals. Ear: Pharmacol. (2001) 431:189–200.
   PubMed Web of Science ®Google Scholar
• LACHOWICZ JE, DUFFY RA, RUPERTO V et al.: Facilitation of acetylcholine release and improvement in cognition by a selective M2 muscarinic antagonist, SCH 72788. Life Sci. 68: 2585–2592.
   Google Scholar
• PARSONS CG, DANYSZ W, QUACK G: Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology (1999) 38:735–767.
   PubMed Web of Science ®Google Scholar
• MIGUEL-HIDALGO JJ, ALVAREZ XA,CACABELOS R, QUACK G: Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40). Brazil Res. (2002) 958:210–221.
   Web of Science ®Google Scholar
• WINBLAD B, PORITIS N: Memantine in severe dementia: results of the 9M-Best Study (benefit and efficacy in severely demented patients during treatment with memantine). Int. I avian: Psychiatry (1999) 14:135–146.
   Google Scholar
• ORGOGOZO JM, RIGAUD AS, STOFFLER A, MOBIUS HJ, FORETTE F: Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke (2002) 33: 1834-1839.
   Google Scholar
• WILCOCK G, MOBIUS HJ, STOFFLER A: A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia. (MMM5000). bit. Clin. Psychopharmacol. (2002) 6:297–305.
   Google Scholar
• REISBERG B, DOODY R, STOFFER A et al.: Memantine in moderate-to-severe Alzheimer's disease. N Engl. Med. (2003) 348:1333–1341.
   PubMed Web of Science ®Google Scholar
• CASSEL JC, JELTSCH H: Serotonergic modulation of cholinergic function in the central nervous system: cognitive implications. Neuroscience (1995) 69:1–41.
   PubMed Web of Science ®Google Scholar
• STECKLER T, SAGHAL A: The role of serotonergic-cholinergic interactions in the mediation of cognitive behaviour. Behav. Brain Res. (1995) 67:165–199.
   PubMed Web of Science ®Google Scholar
• LANCTOT K, HERMANN N, MAZZOTTA P: Role of serotonin in the behavioural and psychological symptoms of dementia. I Neuropsychiany Clin. Neurosci. (2001) 13:5–21.
   PubMed Web of Science ®Google Scholar
• MENESES A: Physiological, pathophysiological and therapeutic roles of 5HT in learning and memory. Rev Neurosci. (1998) 9:1–13.
   PubMedGoogle Scholar
• BUHOT MC, MARTIN S, SEGU L: Role of serotonin in memory impairment. Ann. Med. (2000) 32:210–221.
   PubMed Web of Science ®Google Scholar
• •This article provides a comprehensive review of the proposed roles of the 5-HT receptor subtypes in memory and learning under various conditions, and the interaction between these receptors and other transmitter systems.
   Google Scholar
• TECOTT LH, LOGUE SF, WEHNER JM, KAUER JA: Perturbed dentate gyrus function in serotonin 5HT2c receptor mutant mice. Proc. Nati Acad. Sci. USA (1998) 95:15026–15031.
   PubMed Web of Science ®Google Scholar
• NITSCH RM, DENG M, GROWDON JH, WURTMAN RJ: Serotonin 5HT2A and 5HT2c receptors stimulate amyloid precursor protein ectodomain secretion. J. Biol. Chem. (1996) 271:4188–4194.
   PubMed Web of Science ®Google Scholar
• ARJONA AA, POOLER AM, LEE RK, WURTMAN RJ: Effect of a 5HT2c agonist, dexnorfenfluramine, on amyloid precursor protein metabolism in Guinea pigs. Brain Res. (2002) 951:135–140.
   PubMed Web of Science ®Google Scholar
• ALHAIDER AA, AGEEL AM, GINAWI OT: The quipazine and YFMPP-increased conditioned avoidance response in rats: Role of 5HT1c/5HT2 receptors. Neuropharmacology (1993) 32:1427–1432.
   PubMed Web of Science ®Google Scholar
• JAKEMAN LB, ID ZP, EGLEN RM, WONG EHF, BONHAUS DW: Quantitative autoradiography of 5HT4 receptors in brains of three species using two structurally distinct radioligands, [3H]GR113808 and [3H]BIMU-1. Neuropharmacology (1994) 33:1027–1038.
   PubMed Web of Science ®Google Scholar
• COMPAN V, DASZUTA A, SALIN P et al.: Lesion study of the distribution of serotonin 5HT-4 receptors in rat basal ganglia and hippocampus. Ear: Neurosci. (1996) 8:2591–2598.
   PubMed Web of Science ®Google Scholar
• REYNOLDS GP, MASON SL, MELDRUM A et al.: 5-hydroxytryptamine (5HT) 4 receptors in post mortem human brain tissue: distribution, pharmacology and effects of neurodegenerative diseases. Br. Pharmacol. (1995) 114:993–998.
   PubMed Web of Science ®Google Scholar
• ROBERT SJ, ZUGAZA JL, FISCHMEISTER R, GARDIER AM, LEZOUALCH F: The human 5-HT4 receptor regulates secretion of non-amyloidogenic precursor protein. Biol. Chem. (2001) 276:44881–44888.
   Web of Science ®Google Scholar
• MARCHETTI E, DUMUIS A, BOCKAERT J, SOUMIREU- MOURAT B, ROMAN FS: Differential modulation of the 5-HT4 receptor agonists and antagonists on rat learning and memory. Neuropharmacology (2000) 39: 2017-2027.
   Google Scholar
• EGLEN RM, WONG EHF, DUMUIS A, BOCKAERT J: Central 5HT4 receptors. Trends Pharmacol Sci. (1995) 16:391–398.
   PubMed Web of Science ®Google Scholar
• LAMIRAULT L, SIMON H: Enhancement of place and object recognition memory in young adult and old rats by RS 67333. Neuropharmacology (2001) 41:844–853.
   PubMed Web of Science ®Google Scholar
• GALEOTTI N, GHELARDINI C, BARTOLINI A: Role of 5-HT4 receptors in the mouse passive avoidance test. Pharmacol Exp. The]: (1998) 286:1115–1121.
   Google Scholar
• MOSER PC, BERGIS OE, JEGHAM S et al: 5L65.0155, a novel 5-hydroxytryptamine4receptor partial agonist with potent cognition-enhancing properties. Pharmacol Exp. The]: (2002) 302:731–741.
   Google Scholar
• BUHOT MC: Serotonin receptors in cognitive behaviours. Curt: Opin. Neurobiol (1997) 7:243–254.
   PubMed Web of Science ®Google Scholar
• FLETCHER A, BILL DJ, BILL AJ et al: WAY 100135: a novel, selective antagonist at presynaptic and postsynaptic 5HT14, receptors. Eur.J Pharmacol (1993) 237:283–291.
   PubMed Web of Science ®Google Scholar
• CARLI M, LUSCHI R, SAMANIN R: (S)-WAY 100135, a 5HT14, receptor antagonist, prevents the impairment of spatial learning caused by intra-hippocampal scopolamine. Ear. J. Pharmacol (1995) 283:133–139.
   PubMed Web of Science ®Google Scholar
• CARLI M, LUSCHI R, GAROFALO P, SAMANIN R: 8-0H-DPAT impairs spatial but not visual learning in a water maze by stimulating 5HT1A receptors in the hippocampus. Behav. Brain Res. (1995) 67:67–74.
   PubMed Web of Science ®Google Scholar
• MELLO-E-SOUZA T, RODRIGUES C, SOUZA M et al.: Involvement of the serotonergic Type 1A (5HT1A) receptor in the agranular insular cortex in the consolidation of memory for inhibitory avoidance in rats. Behav. Pharmacol (2001) 12:349–353.
   PubMed Web of Science ®Google Scholar
• FLETCHER A, FORSTER EA, BILL DJ et al.: Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT 1A receptor antagonist. Behav. Brain Res. (1996) 73:337–353.
   PubMed Web of Science ®Google Scholar
• CARLI M, BONALUMI P, SAMANIN R: WAY-100635, a 5-HT 14, receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal administration of scopolamine or 7-chloro-kynurenic acid. Brain Res. (1997) 774:167–174.
   PubMed Web of Science ®Google Scholar
• MISANE I, OGREN SO: Selective 5-HT1A antagonists WAY 100635 and NAD 299 attenuate the impairment of passive avoidance caused by scopolamine in the rat. Neuropsychopharmacology (2003) 28:253–264.
   PubMed Web of Science ®Google Scholar
• CARLI M, SILVA S, BALDUCCI C, SAMANIN R: WAY-100635, a 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by blockade of hippocampal NMDA receptors. Neuropharmacology (1999) 38:1165–1173.
   PubMed Web of Science ®Google Scholar
• BOAST C, BARTOLOMEO AC, MORRIS H, MOYER JA: 5-HT antagonists attenuate MK801-impaired radial arm maze performance in rats. Neurobiol Learn. Mem. (1999) 71:259–271.
   PubMed Web of Science ®Google Scholar
• JOHANSSEN L, SOHN D, THORBERG SO et al: The pharmacological characterisation of a novel selective 5-hydroxytryptamine 1A receptor antagonist, NAD-299. I Pharm. Exp. Ther. (1997) 283:216–225.
   Web of Science ®Google Scholar
• FONTANA DJ, DANIELS SE, HENDERSON C, EGLEN RM, WONG EHF: Ondansetron improves cognitive performance in the Morris water maze spatial navigation task. Psychopharmacology (1995) 120:409–417.
   PubMed Web of Science ®Google Scholar
• PITSIKAS N, BORSINI F: Different effects of tropisetron and ondansetron in learning and memory paradigms. Pharmacol Biochem. Behav (1997) 56:571–576.
   PubMed Web of Science ®Google Scholar
• ARNSTEN AF, LIN CH, VAN-DYCK CH, STANHOPE KJ: The effects of 5-HT3 receptor antagonists on cognitive performance in aged monkeys. Neurobiol Aging (1997) 18:21–28.
   PubMed Web of Science ®Google Scholar
• LETTY S, CHILD R, DUMUIS A et al: 5-HT4 receptors improve social olfactory memory in the rat. Neuropharmacology (1997) 36:681–687.
   PubMed Web of Science ®Google Scholar
• TERRY AV, BUCCAFUSCO JJ, PRENDERGAST MA et al: The 5HT3 receptor antagonist RS-56812 enhances delayed matching performances in monkeys. Neuroreport (1996) 8:49–54.
   PubMed Web of Science ®Google Scholar
• RUBINOW DR, DAVIS CL, POST RM: Somatostatin in neuropsychiatric disorders. Basic Clin. Aspects NeuroscL (1992) 4:30–42.
   Google Scholar
• DAVIES P, KATZMAN R, TERRY RD: Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer's disease and Alzheimer senile dementia. Nature (1980) 288:279–280.
   PubMed Web of Science ®Google Scholar
• JOHANSSON 0, HOKFELT T, ELDE RP: Immunohistochemical distribution of somatostatin-like immunoreactivity in the central nervous system of the adult rat. Neuroscience (1984) 13:265–339.
   PubMed Web of Science ®Google Scholar
• MATSUOKA N, KANEKO S, SATOH M: Somatostatin augments long-term potentiation of the mossy fiber-CA3 system in guinea-pig hippocampal slices. Brain Res. (1991) 553:188–194.
   PubMed Web of Science ®Google Scholar
• MATSUOKA N, MAEDA N, YAMAGUCHI I, SATOH M: Possible involvement of brain Somatostatin in the memory formation of rats and the cognitive enhancing action of FR121196 in passive avoidance task. Brain Res. (1994) 642:11–19.
   PubMed Web of Science ®Google Scholar
• INOUE T, WANG F, MORIGUCHI A et al.: FK960, a novel potential anti-dementia drug, enhances high K(+)-evoked release of somatostatin from rat hippocampal slices. Brain Res. (2001) 892:111–117.
   PubMed Web of Science ®Google Scholar
• MATSUOKA N, AIGNER T: FK960 (N-(4-acety1-1-piperaziny1)-p-fluorobenzamide Monohydrate) a novel anti-dementia drug, improves visual recognition memory in Rhesus monkeys: comparison with physostigmine. Pharmacol Exp. Ther. (1996) 280:1201–1209.
   Web of Science ®Google Scholar
• MORIGUCHI A, NAKANO K, YAMAGUCHI I et al.: FK960, a potential anti-dementia drug, increases synaptic density in the hippocampal CA3 region of aged rats. Brazil Res. (2002) 958:381–389.
   Web of Science ®Google Scholar
• TOKITA K, YAMAZAKI S, YAMAZAKI M, MATSUOKA N, MUTOH S: Combination of a novel antidementia drug FK960 with donezepil synergistically improves memory deficits in rats. Pharm. Biochem. Behav. (2002) 73:511–519.
   PubMed Web of Science ®Google Scholar
• TOZAKI H, KANNO T, NOMURA T et al.: Role of glial glutamate transporters in the facilitatory action of FK960 on hippocampal transmission. Brazil Res. Ma Brain Res. (2001) 97:7–12.
   PubMedGoogle Scholar
• HODGKISS JP, KELLY JS: Effect of FK 960, a putative cognitive enhancer, on synaptic transmission in CA1 neurons of rat hippocampus. I Pharmacol Exp. Ther. (2001) 297:620–628.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI K, YASOSHIMA Y: The central noradrenaline system and memory consolidation. Neuroscientist (2001) 7:371–376.
   PubMed Web of Science ®Google Scholar
• FRANOWICZ JS, KESSLER LE, BORJA CM, KOBILKA BK, LIMBIRD LE, ARNSTEN AF: Mutation of the alpha2A-adrenoceptor impairs working memory performance and annuls cognitive enhancement by guanfacine. Neurosci. (2002) 22:8771–8777.
   PubMed Web of Science ®Google Scholar
• MATTHEWS KL, CHEN CP, ESIRI MM, KEENE J, MINGER SL, FRANCIS PT: Noradrenergic changes, aggressive behavior, and cognition in patients with dementia. Biol. Psychiatry (2002) 51:407–416.
   PubMed Web of Science ®Google Scholar
• RIEKKINEN P Jr, RIEKKINEN M: THA improves word priming and clonidine enhances fluency and working memory in Alzheimer's disease. Neuropsychophapnacology (1999) 20:357–364.
   PubMed Web of Science ®Google Scholar
• RIEKKINEN M, LAAKSO MP, JAKAL P: Clonidine impairs sustained attention and memory in Alzheimer's disease. Neuroscience (1999) 92:975–982.
   PubMed Web of Science ®Google Scholar
• FRANOWICZ JS, ARNSTEN AF: Actions of a-2 noradrenergic agonists on spatial working memory and blood pressure in rhesus monkeys appear to be mediated by the same receptor subtype. Psychophapnacology (2002) 162:304–312.
   PubMed Web of Science ®Google Scholar